IFM Therapeutics

United States
Panora, Iowa, United States, 02199

Company profile

IFM Therapeutics company profile

IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

Business identity

Contact email
[email protected]
Phone number
+1-857-327-9903
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2015-01-01, Year

Headquarters

Postal code
02199
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$82.5M
Last funding
Series Unknown / $55.5M / 2019-12-02
Last equity funding
Series Unknown / $55.5M
Investors
4
Lead investors
2
Founders
5
Articles
35
Exited on
2017-08-03

Founders and investors

Founders

Anthony OpipariEicke LatzGary GlickLuigi FranchiMatthias Geyer

Lead investors

Atlas VentureOmega Funds

Investors

AbingworthAtlas VentureNovartisOmega Funds